GlassScriptPhysician profile
David Lawrence Moody
NPI 1346359197
$3,767.19
in general payments reported to CMS, 2019-2025
35 companies · $449 in 2025
The $449 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $597 · 2020: $677 · 2021: $671 · 2022: $432 · 2023: $504 · 2024: $438 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,391.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $600.15 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $515.51 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $385.59 | 2019-2023 | Austedo |
| Astrazeneca Pharmaceuticals LP | $354.47 | 2020-2025 | Breztri, Farxiga |
| Glaxosmithkline, LLC. | $267.69 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $214.45 | 2019-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $177.99 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $173.33 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $103.22 | 2025 | Purified Cortrophin Gel |
| Astellas Pharma US INC | $102.07 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $89.56 | 2024-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $82.16 | 2019-2023 | Trintellix |
| Pfizer INC. | $81.02 | 2019-2024 | |
| Amgen INC. | $74.72 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $71.60 | 2023-2024 | Rexulti |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $46.59 | 2021-2025 | |
| Avanir Pharmaceuticals, INC. | $43.98 | 2021-2022 | |
| Sk Life Science, INC. | $40.95 | 2021 | |
| Averitas Pharma INC. | $38.83 | 2025 | Qutenza |
| Allergan, INC. | $37.82 | 2019-2020 | |
| Grifols USA, LLC | $30.14 | 2020 | |
| Merck Sharp & Dohme LLC | $29.88 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.17 | 2024 | |
| Lundbeck LLC | $22.07 | 2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $16.44 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.18 | 2022 | |
| Medtronic, INC. | $15.87 | 2022 | |
| Vanda Pharmaceuticals INC. | $15.60 | 2024 | Fanapt |
| Lilly USA, LLC | $14.90 | 2023 | Mounjaro |
| Paratek Pharmaceuticals, INC. | $14.66 | 2024 | Nuzyra |
| Eisai INC. | $12.97 | 2020 | |
| Sanofi-Aventis U.S. LLC | $12.71 | 2022 | |
| Scilex Pharmaceuticals INC. | $12.34 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.73 | 2020 | |
| Genentech USA, INC. | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Moody listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.